KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Account Payables (2016 - 2020)

Historic Change in Account Payables for Supernus Pharmaceuticals (SUPN) over the last 7 years, with Q3 2020 value amounting to $5.7 million.

  • Supernus Pharmaceuticals' Change in Account Payables rose 56491.8% to $5.7 million in Q3 2020 from the same period last year, while for Sep 2020 it was $5.8 million, marking a year-over-year increase of 18267.41%. This contributed to the annual value of $7.0 million for FY2019, which is 29457.8% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Change in Account Payables stood at $5.7 million for Q3 2020, which was up 56491.8% from -$182000.0 recorded in Q2 2020.
  • In the past 5 years, Supernus Pharmaceuticals' Change in Account Payables registered a high of $7.3 million during Q4 2019, and its lowest value of -$7.0 million during Q1 2020.
  • For the 5-year period, Supernus Pharmaceuticals' Change in Account Payables averaged around $247736.8, with its median value being -$380000.0 (2016).
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Change in Account Payables soared by 93763.16% in 2017, and later tumbled by 106011.56% in 2018.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Account Payables (Quarter) stood at $5.1 million in 2016, then plummeted by 86.43% to $692000.0 in 2017, then plummeted by 1060.12% to -$6.6 million in 2018, then skyrocketed by 209.81% to $7.3 million in 2019, then fell by 22.26% to $5.7 million in 2020.
  • Its Change in Account Payables stands at $5.7 million for Q3 2020, versus -$182000.0 for Q2 2020 and -$7.0 million for Q1 2020.